Company Overview

IMV Inc. is a Canadian biotechnology company focused on the development of immunotherapies and vaccines using its proprietary lipid-based delivery platform known as DPX. The company has historically operated within the biotechnology and pharmaceutical research industries, with a primary emphasis on oncology and infectious disease applications. IMV’s development programs have centered on activating targeted immune responses through T-cell–based therapies, particularly in hematologic cancers and solid tumors.

The company’s principal value driver has been its DPX platform technology, which was designed to improve antigen delivery and sustain immune activation. IMV’s lead clinical candidate was Maveropepimut-S (MVP-S), previously studied in ovarian cancer and diffuse large B-cell lymphoma. IMV was founded in Canada and evolved from vaccine research initiatives into a clinical-stage immuno-oncology company listed on public markets in both Canada and the United States. Public disclosures and court-related filings indicate that the company experienced significant financial distress beginning in 2023, including creditor protection proceedings and restructuring activities. Certain aspects of the company’s current operating status are data inconclusive based on available public sources.

Business Operations

IMV historically operated as a single biotechnology-focused enterprise centered around its DPX immunotherapy platform and associated clinical development programs. Revenue generation was limited, as the company primarily functioned as a clinical-stage biotechnology issuer without commercialized pharmaceutical products. Funding historically came from equity offerings, strategic collaborations, grants, and licensing-related activities rather than recurring product sales.

The company maintained research and development operations in Canada and conducted clinical trial activities in collaboration with hospitals, research institutions, and oncology centers in multiple jurisdictions, including the United States. IMV controlled intellectual property associated with the DPX platform, including formulation and delivery technologies intended to enhance immune response durability. Public filings referenced collaborations with academic and clinical partners tied to oncology studies and vaccine development initiatives. Information regarding currently active subsidiaries, ongoing joint ventures, or continuing operational infrastructure remains limited in recent public disclosures.

Strategic Position & Investments

IMV’s strategic direction focused on advancing immunotherapy candidates capable of producing durable anti-cancer immune responses while differentiating itself from traditional vaccine adjuvant systems. The company invested heavily in clinical development programs tied to Maveropepimut-S (MVP-S) and earlier infectious disease vaccine candidates utilizing the DPX platform. Its strategy emphasized combination therapies involving checkpoint inhibitors and other immuno-oncology agents.

The company pursued capital raises and strategic partnerships to finance clinical trials and platform expansion. Publicly disclosed initiatives included collaborations associated with lymphoma and ovarian cancer research, as well as exploratory work in infectious disease applications. However, restructuring proceedings and liquidity constraints materially affected IMV’s ability to continue executing its long-term commercialization strategy. Available public information indicates that several planned development activities were delayed, suspended, or reevaluated during the restructuring process.

Geographic Footprint

IMV was headquartered in Dartmouth, Nova Scotia, Canada, and maintained operational ties to research and clinical development networks across North America. The company’s clinical studies involved sites in both Canada and the United States, reflecting its focus on accessing major oncology treatment and research markets.

While IMV did not operate as a large multinational pharmaceutical company, it maintained visibility in international biotechnology and immunotherapy sectors through conference participation, cross-border clinical activity, and publicly traded market access. Its investor base and regulatory engagement extended into the United States through its U.S. market listing and related securities filings.

Leadership & Governance

IMV’s leadership historically consisted of biotechnology executives and scientific personnel with backgrounds in immunology, oncology, pharmaceutical development, and capital markets. Strategic leadership emphasized advancement of the DPX platform and progression of clinical-stage oncology assets through partnership-driven development models. Leadership changes occurred during periods of financial restructuring and operational transition.

Key executives and leaders publicly associated with IMV during its later operating period included:

• Andrew Hall – Chief Executive Officer
• Marianne Stanford – Chief Financial Officer
• Frederic Ors – Chief Executive Officer (former)
• Marcie Barber – Chief Operating Officer and Chief Scientific Officer (former)
• Brian Schmidt – Chair of the Board

Certain executive appointments and governance roles changed during restructuring proceedings, and some information regarding current leadership status is data inconclusive based on available public sources.